Company / Return on Equity (ROE)
Kodiak Sciences Inc. Return on Equity (ROE) History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-117.3%
FY2024
5-year range
-117.3% / -15.5%
FY2020-FY2024
Trend
-19.6%
vs FY2023
Sector context
#168 of 190
Health Care
What the data says
Kodiak Sciences Inc. reports negative total equity of -117.3% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-117.3% in FY2024 with a 5-year CAGR of -103.5%.
Declined from -76.5% to -117.3% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -77.0pp
- 5-Year Change
- -103.5pp
- 10-Year Change
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 190This company -117.3% Sector average -50.3%
▼
-133.1% below sector average
Key checks
Key Insights
- Kodiak Sciences Inc.'s return on equity (roe) has declined for 5 consecutive years.
- In FY2024, return on equity (roe) decreased 19.6% year-over-year.
- Currently 66.9pp below the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -117.3% | -19.6% |
| FY2023 | -98.0% | -28.1% |
| FY2022 | -76.5% | -90.2% |
| FY2021 | -40.3% | -160.3% |
| FY2020 | -15.5% | -12.8% |
| FY2019 | -13.7% | +71.3% |
| FY2018 | -47.7% | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026